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} conjugates are recognized by intracellular enzymes and converted to coenzyme B 12 in an enzymatic adenosylation assay. The reductive adenosylation of {B 12 -CN-Pt II } conjugates leads to the release of the Pt II complexes; thus, {B 12 -CN-Pt II } conjugates can be considered as prodrugs. It is important not only to elucidate the activity of the cisplatin-B 12 conjugates, but also to understand the mode of action on a molecular level. Chemical reduction of {B 12 
Introduction
The treatment of diseases in current medicine widely relies on the administration of target-specific but cellreceptor-unspecific pharmaceuticals. Cell-specific targeted drug delivery has, however, become a major issue in modern molecular approaches to drug design and discovery [1] . Ideally, a pharmaceutical exclusively accumulates at the target site and is readily eliminated from the rest of the body. Much current research is, thus, currently performed in the field of targeted drug delivery, based on nanoparticles, organic copolymers, but also with small receptor binding molecules [2] [3] [4] [5] [6] . The targeted drug delivery concept relies on natural or artificial molecules which carry their bioactive load to a specific site. At this site, the pharmaceutical is released and exerts its activity. The feature of targeting is particularly crucial in molecular imaging since the quality of the images depends strongly on the target to nontarget ratio; thus, the more specific the targeting, the better the interpretation of the images [7, 8] . There are numerous modalities Electronic supplementary material The online version of this article (doi:10.1007/s00775-010-0697-z) contains supplementary material, which is available to authorized users.
for targeting, encompassing in, e.g., nanomedicine, artificial macromolecules such as dendrimers, carbon nanotubes, or polyoxometallates derivatized with cell-specific receptor binding functions such as antibodies, peptides, or small molecules (and the bioactive substance). Metabolic tracers are another class of targeting molecules in molecular imaging but not in therapy; they accumulate owing to rapid proliferation of cells. A prototype for such compounds is 18 F-deoxyglucose [9] , which is trapped in cells by irreversible inhibition of hexokinase. With the same concept, bioactive drugs guided by targeting (small) molecules could be delivered to specific sites provided that these bioconjugates still follow the same metabolic pathway. Furthermore, intracellular biochemical processes have to be involved in the release of the drug after delivery to the cell but not elsewhere. Whereas targeted cancer therapy with antibodies is well developed, small carrier molecules are still rare. One of the major problems related to small-molecule conjugation of bioactive substances is the affection of the biological properties of the carrier after conjugation to the imaging agent or pharmaceutical.
Cobalamin (Cbl, vitamin B 12 ) is essential for mammals. Different cancer cell lines express a strongly increased demand for Cbl. Cbl has been radiolabeled at various sites on the corrin framework, generally on the b, d, or e propionamide chain of Cbl after hydrolysis to the corresponding acids (Scheme 1) [10] [11] [12] [13] [14] [15] [16] [17] . Those radiolabeled Cbl showed high tumor accumulation, confirming their adequacy as metabolic tracers and suitability for imaging [18] . We showed recently that 99m Tc-labeled Cbl derivatives not binding to the transport protein transcobalamin II (TCII) showed high site-specific accumulation and very low kidney retention [19] .
Whereas derivatizations with metal binding functionalities or bioactive molecules were generally performed at the propionamide groups of the coring ring, at the 2 0 -OH group in the ribose [20] [21] [22] , or by alkylation of Co I [23] [24] [25] [26] , we have demonstrated that metal complexes can be bound directly to the cyanide group in Cbl, thereby yielding a heterodinuclear complex {B 12 -CN-M} in which Cbl acts as a ligand [27] . In particular, cyanide in Cbl coordinated to various square-planar Pt II complexes such as cisplatin [28] . With Pt II complexes in particular, the central {B 12 -CN-Pt II } motif was formed. An enzymatic assay showed that these B 12 -Pt conjugates were still recognized by intracellular adenosylation enzymes and were converted to adenosylcobalamin (AdoCbl) [29] Numerous Pt II complexes have been screened for cytotoxicity during the search for cisplatin analogues with cytotoxic activity [30] . However, the Pt II complexes as released from 1-3 (Scheme 2) are cisplatin-like but not cisplatin. Besides NH 3 and Cl, they contain one coordinated cyanide. To our knowledge, the cytotoxicity of these basic Pt II complexes is not known since they are synthetically difficult to access and have not been described in literature. Accordingly, we present the bioactivity of these complexes to assess their cytotoxicity after release from the carrier B 12 together with studies of the reactivity of the released complexes toward nucleotides as models for the DNA binding sites of cisplatin (analogues).
Materials and methods

General
All chemicals were purchased from Sigma, Fluka, and Strem. Chemicals were of reagent grade and used without further purification. The vitamin B 12 complexes 1-3 were synthesized according to published procedures [29] . Ultraperformance liquid chromatography (UPLC) analyses were performed using a Waters Acquity TM connected to an HCT ion trap mass spectrometer (Bruker Daltonics). The following liquid chromatography (LC) column, solvent systems, and gradient were used: column, Macherey-Nagel C-18ec Nucleosil RP (5-lm particle size, 100-Å pore size, 250 mm 9 3 mm); solvent system 1, 0.1% trifluoroacetic acid (solvent A), methanol (solvent B); solvent system 2, 0.1% formic acid (solvent A), methanol (solvent B); solvent system 3, 10 mM Et3Nac, pH 4.6 (solvent A), methanol (solvent B); gradient 1, 0-5 min (75% solvent A), 5-30 min (75% solvent A ? 0% solventA); gradient 2, 0-5 min (100% solvent A), 5-30 min (100% solvent A ? 0% solvent A).
Chemical reduction of complexes 1-3
Reduction of cob(III)alamin to cob(II)alamin of derivatives 1-3 was performed in methanol, under a N 2 atmosphere, using 2 equiv of cobaltocene. Formation of cob(II)alamin was monitored by UV-vis spectroscopy. The formation of platinum complexes in the reaction mixture after release from derivatives 1-3 was monitored by electrospray ionization (ESI) mass spectrometry (MS) and high performance LC (HPLC) measurements (solvent system 1, gradient 1, flow rate 0.5 mL min -1 ) and the formation of HOCbl. ? (8).
• 2 0 -Deoxyguanosine interaction. 1 (6.5 lmol) was reduced with cobaltocene (2 equiv) in methanol. After the mixture had been stirred for 30 min, the solvent was evaporated and the crude mixture was dissolved in Kinetic interaction of GMP with cisplatin, 4, and 5
Complexes 1 and 2 (both 6.5 lmol) were reduced with 2 equiv of cobaltocene in methanol. After 30 min, the solvent was evaporated and the crude mixture was dissolved in 1.5 mL PBS. The solution was filtered and added to 50 equiv of GMP. The reaction was followed by UPLC-MS every 4 h (solvent system 3, gradient 2, flow rate 0.3 mL min -1 ). As a control experiment, the reaction of 6.5 lmol cisplatin with 50 equiv of GMP in 1.5 mL PBS was followed by UPLC-MS every 4 h under the same conditions.
Cell lines
The human breast carcinoma MCF7 cell line was maintained in minimum Eagle's essential medium (MEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco), penicillin (100 U mL -1 ), and streptomycin (100 lg mL -1 ). The human ovarian cancer A2780 cell line was maintained in RPMI (Gibco) supplemented with 10% FBS (Gibco), penicillin (100 U mL -1 ), and streptomycin (100 lg mL -1 ).
One thousand cells per well were seeded in 96-well plates 1 day before treatment. Cells were treated with cisplatin, B 12 , cobaltocenium, 1, 2, 3, 4, 5, or 6 for 5 days, the drug was removed, and cells were kept in fresh medium. Upon addition of 20 lL per well of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg mL -1 ), the plates were incubated for 4-5 h at 37°C. One hundred microliters per well of lysis buffer (20% sodium dodecyl sulfate, 50% dimethylformamide, 50% double-distilled H 2 O, pH \ 4.7) was added and the plates were incubated overnight at 37°C. The solubilized formazan was quantified at 570 nm using a SpectraMax M5 microplate reader. Optical density values were plotted against the logarithm of drug (or derivative) concentration and IC 50 values were calculated from the regression curve.
Cbl/TCII MTT assay
To ensure a Cbl-dependent cytotoxic effect, RPMI deficient in Cbl and folic acid (medium A) or MEM (Gibco) (medium B), which does not contain Cbl in the original formulation, was used. FBS was pretreated with fumed silica to reduce interference of endogenous TCII/Cbl in the assay [31] . One thousand cells per well were seeded in 96-well plates 1 day before treatment using standard medium. After removal of the growth medium, the cells were treated with cisplatin or with 1, 2, or 3, or with 1, 2, or 3 in the presence of 1 equiv of TCII for 1 day in medium A or medium B containing 10% treated FBS. The drug was removed and the cells were kept in fresh medium for an additional 4 days. Upon addition of 20 lL per well of MTT solution (5 mg mL -1 ), the plates were incubated for 4-5 h at 37°C. One hundred microliters per well of lysis buffer (20% sodium dodecyl sulfate, 50% dimethylformamide, 50% double-distilled H 2 O, pH \ 4.7) was added and the plates were incubated overnight at 37°C. The solubilized formazan was quantified at 570 nm using a SpectraMax M5 microplate reader.
Immunofluorescence
Indirect immunofluorescence experiments were performed with MCF7 cells grown on glass coverslips. Upon fixation in methanol (15 min, -20°C), the cells were washed with PBS. Blocking was carried out in PBS supplemented with 3% nonfat dry milk (blocking solution). The coverslips were incubated overnight at 4°C in a humidified chamber with c-H2AX (pSer 139 ) antibody (mouse monoclonal, Upstate Biotechnology) diluted 1:200 in blocking solution. After they had been washed with blocking solution, the cells were incubated with a Texas Red conjugated anti-mouse antibody at 1:200 dilution in blocking solution for 1 h at 37°C. The nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (0.1 lg mL -1 , Sigma). Images were acquired using an Olympus IX81 fluorescence microscope.
Results and discussion
Reduction of Co(III) to Co(II) and isolation of the released Pt(II) complexes
The enzymatic conversion of {B 12 -CN-Pt II } derivatives to AdoCbl by CobA enzyme has been reported previously [29] . The corrinoid adenosylation pathway proposed required the electron-transfer protein flavodoxin FldA and the ferrodoxin Fpr as reductases for the Co III ? Co II step. Only in the presence of the corresponding enzyme and ATP did further reduction of Co II to Co I take place with concomitant formation of AdoCbl [32, 33] . For the purpose of targeted metal complex delivery in our study, the first reduction step is decisive. The Pt II complexes from Cbl derivatives 1-3 (Scheme 2) are released into the intracellular space after the Cbl has entered the cells by receptormediated endocytosis via the TCII receptor, but not before. The release of the platinum complexes from 1-3 occurs after enzymatic reduction of Co III to Co II . The remaining cob(II)alamin is then reduced to Co I and adenosylated to coenzyme AdoCbl by adenosyltransferase [29] . After reduction to Co II , the composition of the released Pt II complexes is an important question and, in particular, if the cyanide ligand is still present on the released Pt II complex or is lost during reduction. It should be emphasized that the cyanide is N-bound to Pt II in {B 12 -CN-Pt II } and it would be uncommon to find an {Pt-NC} motif in the released complex. Compounds 1-3 were electrochemically reduced to release the b-axial complexes 4-6. After reduction, HPLC evidenced the presence of exclusively aquo-Cbl, assessing the cleavage of the complexes together with the cyanide ligand. Although this is a very smooth and straightforward method, the presence of large amounts of supporting electrolyte as compared with the tiny amounts of Pt II complex made their characterization or isolation impossible. Chemical reduction was more appropriate since inert salts are absent and the process is faster. An appropriate reducing agent is cobaltocene. Cobaltocene is a noncoordinating molecule with a redox potential of about -750 mV (vs. Ag ? /AgCl) in methanol. This agent is ideal for reduction of cob(III)alamin to cob(II)alamin and does not further reduce Co II or the released platinum complexes. Quantitative chemical reduction of 1-3 was smoothly achieved with 2 equiv of cobaltocene in methanol and under N 2 . The reaction was complete after 30 min at room temperature. A typical UV-vis spectrum of the cob(II) alamin produced together with an HPLC trace for HOCbl formation is shown in Fig. 1 .
The isolation of complexes 4 from 1, 5 from 2, and 6 from 3 (Scheme 3), released after cobaltocene reduction, was not directly possible owing to the respective low concentrations and insolubilities. Owing to their electroneutrality, compounds 4 and 6 as well as pure cisplatin were not observed in ESI-MS. However -remained almost constant (-73.9 pm), whereas the second signal (-40.7 ppm) shifted significantly to lower field. Since cyanide is a very strong trans ligand, the latter signal indicated the presence of a cyanide trans to 15 NH 3 , thereby further rationalizing the authenticity of 4 (see the electronic supplementary material).
Dimethyl sulfoxide (dmso) is known to substitute Cl -in Pt II complexes [38] . Addition of dmso to the reaction solution of 3 after cobaltocene reduction allowed for the clear mass-spectrometric detection of trans-[Pt(CN)(dmso) (NH 3 
? . Although the signals were weak, the mass spectra indicated that cyanide is still coordinated to the released Pt II complexes after reduction of 1-3 (see the electronic supplementary material). An alternative method for the characterization of the released platinum complexes relied on the Kurnakov test, a method which allows one to distinguish cis and trans isomers of dihalide-diamine Pt II complexes [39] After reduction of 1-3 with cobaltocene, mixtures of HOCbl and the respective Pt II complexes 4-6 were formed. The solvent was evaporated and the red residues were dissolved in water containing a tenfold excess of thiourea. After 30 min, the sample was filtered and analyzed by LC-MS. In all three cases, HOCbl was observed. The substitution reactions were fast and product formation was complete after 1 h at a platinum-to-thiourea ratio of 1:10. Since cyanide has a very strong trans effect, the reaction of 4 and 5 with thiourea should give the triply substituted complex [Pt(CN){SC(NH 2 ) 2 } 3 ]
? (7) and the reaction of thiourea with 6, a transplatin-type complex, should give the monosubstituted complex trans-[Pt(CN)(NH 3 ) 2 
{SC(NH 2 )}]
? (8) (Scheme 3). This predicted behavior was confirmed and complexes 7 and 8 could clearly be identified as the major products by HPLC and ESI-MS (see the electronic supplementary material).
Furthermore, complex 7 could be isolated by preparative HPLC as a yellow powder. The 195 Pt NMR spectrum of 7 gave a sharp signal at -4,130 ppm, a region in which resonances of Pt II complexes bound to three sulfur atoms and one carbon atom are usually observed [40, 41] . The infrared spectrum of 7 displayed a weak but characteristic m CN band at 2,187 cm -1 , indicating that the platinum complex was bound to the cyanide ligand via the carbon atom [42] . Inspecting the basic structures of 1-3, we expect that the platinum complex released after reduction will bind the cyanide group via the nitrogen atom. Since all our released complexes 4-6 showed the cyanide to be C-bound, we conclude that isomerization of the cyanide from N-to C-coordination took place very rapidly. The platinum complexes 4-6 as released after chemical or enzymatic reduction of cob(III)alamin in the intracellular space are not cisplatin but cisplatin analogues. The reactivity of these complexes toward their targets, guanine or other nucleobases in DNA, is unknown. To assess the affinity for nucleobases, we studied the interaction of 4-6 with 2 0 -deoxyguanosine (Scheme 4). According to the trans-effect series, in complex 4 one chloride and eventually one NH 3 should be replaced by a base. To mimic physiological conditions, the reaction of, e.g., 4 with 2 0 -deoxyguanosine was performed in 10 mM phosphate buffer (pH 7.4) with 0.9% NaCl as an electrolyte; eightfold excess of 2 0 -deoxyguanosine was applied. After chemical reduction of 1, the formation of products was monitored by LC-MS as a function of time. Single substitution should result in complex 9, and double substitution in complex 10 (Scheme 4). Figure 2 shows Scheme 3 Reaction of complexes 4-6 with thiourea. Cp2Co cobaltocene representative UPLC chromatograms obtained from the extrapolation of mass spectra of the substitution reactions at the time points indicated. After 6 h at room temperature, it is immediately obvious that both complex 9 and complex 10 were formed. Over time, the amount of 9 slowly decreased, whereas the amount of the final product 10 increased. Thus, double substitution on Pt II took place, confirming the cisplatin-like behavior of the complexes cleaved from their Cbl carriers.
To compare the reactivity of 4 and 5 with that of cisplatin, we pursued the same strategy with the dianion 5 0 -GMP (Scheme 5). The Cbl conjugates 1 and 2 were reduced with cobaltocene, dried, and redissolved in 10 mM phosphate buffer and 0.9% NaCl. For a qualitative comparison of the reaction rates, a 50-fold excess of GMP was applied to ensure conditions for pseudo-first-order kinetics. Product formation was monitored by LC-MS as a function of time. The mobile phase used for these experiments was crucial. With 0.1% formic acid in methanol as the mobile phase, protonation of coordinated 5 -(pH 4.6) and methanol as a mobile phase.
Qualitative kinetic measurements were performed for 4 and 5 after release from 1 and 2 and were compared with those for cisplatin. Formation of 5 0 -GMP-substituted derivatives was plotted versus time by extrapolation of the area obtained by UPLC-MS measurements for the individual species.
Other studies typically used the monoaqua and diaqua analogues of cisplatin for kinetic analysis of the reaction of nucleotides and Pt II complexes [43] [44] [45] . In our study, we did not examine the aquation process since it was not observed by ESI-MS. Bancroft et al. [44] 2-, respectively. After about 5 h, the monosubstituted complex reached its maximum concentration (Fig. 3) . The amount of disubstituted complex steadily grew, with complete formation after about 20 h. The behavior of 4 and 5 was qualitatively comparable. Both complexes were substituted by one 5 0 -GMP very rapidly. After less than 1 h, the maximum concentration of monosubstituted compounds 11 and 12 was achieved (see the electronic supplementary material). The kinetics of the second substitution were similar for 11, 12, and cis-[PtCl(GMP)(NH 3 ) 2 ]
-. Formation of the corresponding doubly substituted complex 13 was complete after about 20 h. These kinetics measurements followed qualitatively a consecutive A ? B ? C reaction sequence. The very rapid formation of the monosubstituted adducts 11 and 12 is a very important feature since it enables retention of the cleaved platinum complexes in the cells. Since the kinetics is comparable to that for cisplatin, one could, at least from a chemical point of view, expect similar biological behavior for 4-6.
Cytotoxicity studies
Having established the binding of the new platinum complexes 4-6 with guanine derivatives, we considered it important to investigate the cytotoxicity of these complexes. Complexes 4-6 are the active drugs carried into the cells by Cbl and released after reduction. Reactivity toward 5 0 -GMP is an indication of but not a guarantee for cytotoxicity since other coordination sites may compete for Pt II binding in vivo. We therefore investigated the in vitro cytotoxicity of compounds 4 and 5 with the cancer cell lines A2780 and MCF7. IC 50 values are given in Table 1 . Owing to the essentially nontoxic behavior of 3, the cleavage product 6 was not further investigated. Compound 6 can form only DNA monoadducts, and complexes exerting a cisplatin-like behavior with DNA such as 4 and 5 are immediately more promising. However, it is known that some exceptional, mono-DNA-adduct-forming Pt II complexes are highly cytotoxic [46] . Although the IC 50 values of complexes 4 and 5 are higher than those of cisplatin, they are comparable to those of other cytotoxic or static agents [47] . One should keep in mind that the IC 50 values are not the only quality criteria for successful therapeutic agents and are even sometimes misleading. To evaluate the targeted drug delivery of the {B 12 -CN-Pt II } conjugates, we studied the in vitro cytotoxic behavior of 1-3 in the human breast carcinoma cell line MCF7 and in the human ovarian cancer cell line A2780. We showed in previous studies that the Pt II complexes remain stably bound to Cbl in human serum; hence, any cytotoxicity found must be related to intracellular release of the complexes rather than to decomposition in the media [29] . It should be emphasized that Cbl is bound in vivo to the transport protein TCII [48] . Cellular uptake and internalization of Cbl occurs upon binding of holo-TCII to the membrane TCII receptor (rTCII). After degradation, Cbls are released and enter the enzymatic cycles. Reports in the literature describe the uptake of Cbl derivatives that are TCII nonbinders along so far not fully elucidated pathways [19] . The targeted approach is, however, based on holo-TCII, able to bind rTCII. We initially compared 1-3 with cisplatin despite the fact that the former complexes are prodrug-like compounds, probably unable to freely diffuse into the cell, in contrast to cisplatin. Therefore, in the case of 1-3, the concentration of active platinum complexes in the intracellular space is governed by the rate of internalization and might be significantly lower than what is achieved with cisplatin. As outlined later, the amount of Cbl-Pt conjugates bound to TCII available in the medium is decisive for cytotoxicity, since conjugates not bound to TCII are unlikely to enter the cells.
Cells were plated in 96-well plates at 5,000 cells per well in 100 lL RPMI 1640 or MEM containing 10% of FBS. After 24 h, the cells were treated with cisplatin, 1, 2, and 3 at different concentrations. To assess the potency of 1-3, cell viability after 5 days of treatment with the compounds was evaluated by MTT assays. We found that the Cbl conjugates 1-3 were less active than cisplatin against MCF7 and A2780 cells. Figure 4 shows a concentration-activity comparison. The IC 50 values are given in Table 1 . Conjugate 1 is the most active {B 12 -CN-Pt II } compound, whereas 2 and 3 are essentially inactive. Since the Pt II complex 6 as cleaved from 3 can form only monoadducts with DNA, its nonactivity is reasonable. However, since 4 and 5 as released from 1 and 2, respectively, show the same behavior toward thiourea and 5 0 -GMP (vide infra), the nonactivity of 2 is not immediately obvious. We speculate that there is a diffusion-controlled uptake mechanism (e.g., via cation channels), which would favor the uptake of cationic 1 over neutral 2, resulting in an enhanced cytotoxic effect as observed for 1. For the time being, questions about quantification and the pathway of uptake remain to be elucidated.
Role of TCII
As mentioned before, the plasma transport of Cbl or Cbl derivatives to all tissues or cells is mediated by TCII. Holo-TCII is taken up by receptor-mediated endocytosis via rTCII [49] . Expression of rTCII is important for the cellular uptake of Cbl, although information on the level of rTCII expression in A2780 and MCF7 cell lines is not available to our knowledge. In addition, the concentration of TCII in the cell culture medium determines the level of Cbl-TCII complexes that will undergo internalization [31] . The results of the cytotoxicity assays described earlier might have been influenced by these factors and passive internalization of 1-3 also have to be taken into account. To assess this issue, we set out to determine the effect of TCII on cytotoxicity upon addition of apo-TCII to the media, using very low concentrations of 1-3. To measure TCII/Cbl-dependent cytotoxicity, RPMI 1640 deficient in Cbl and folic acid (medium A) was used for A2780 and commercial MEM (medium B) was used for for MCF7, since the formulation of MEM is deficient in Cbl. The medium was supplemented with 10% FBS pretreated with fumed silica to reduce interference of bovine TCII-Cbl in the bioassay.
Cells were plated in 96-well plates at 1,000 cells per well in 100 lL of medium A or medium B containing 10% pretreated FBS. After 24 h, the cells were treated with cisplatin, compounds 1, 2, apo-TCII ? 1, or apo-TCII ? 2 at 3.125, 1.56, and 0.78 lM. After 24 h the compounds were removed and the cells were kept in standard medium for 4 days. Cell viability was assessed by MTT assays. Figure 5 shows that compounds 1 and 2 were not active at all in the absence of apo-TCII; thus, passive diffusion played a minor role in the observed cytotoxicity. In contrast, in the presence of apo-TCII, analogues 1 and 2 exhibited detectable toxicities even at these low concentrations, indicating that TCII-mediated internalization had occurred.
Interaction with DNA: immunofluorescence studies
Whereas cytotoxicity can be induced by many biological events, it has been thoroughly established for Pt II complexes that DNA strand cross-links are the major mode of Fig. 4 Cytotoxicity of cisplatin, 1, 2, and 3 for MCF7 and A2780 after 5 days of treatment action [38, 44, 50, 51] . The ability of compounds 1, 2, and 5 to interact with DNA and induce DNA damage was investigated by the formation of c-H2AX foci in MCF7 cells. Cells were grown on glass coverslips and treated with 50 lM compound 1, a concentration that corresponds to its IC 90 in the MTT assay and that exerted an effect comparable to that of cisplatin at its IC 90 . As positive control, cells were irradiated with 10 Gy or treated with 3 lM cisplatin (IC 90 ). The cells were examined at the time points indicated (24, 72 , and 144 h). Since the maximum concentration used in the MTT assay was 100 lM, corresponding to IC 35 for compound 2, immunofluorescence studies of compound 1, 2, 5, and cisplatin were carried out using their corresponding IC 35 values (see the electronic supplementary material). As shown in Fig. 6 , 24 h of treatment with compound 1 induced c-H2AX foci displaying an intensity similar to that of cisplatin-treated cells. However, the signal decreased more rapidly in cells treated with compound 1 than in cisplatin-treated cells, likely indicating a more efficient repair in the former case.
Conclusions
We have studied the mode of action of the vitamin B 12 -Pt The reactivity of these cisplatin analogues was studied with thiourea, 2 0 -deoxyguanosine, and GMP. The reactivities of 4 and 5 with GMP compared well with the reactivity of cisplatin. Accordingly, isolated 4 and 5 after B 12 release displayed cytotoxicity comparable to that of cisplatin. Preliminary cytotoxicity studies of 1-3 showed a lower effect than for cisplatin, probably owing to a low, receptor-mediated uptake of the {B 12 -CN-Pt II } conjugates. Addition of apo-TCII to the cell media substantially increased the cytotoxic effect, underlining the limiting aspect of uptake and correlation to cytotoxicity. We conclude that {B 12 -CN-Pt II } conjugates can be considered as prodrugs since they release their cytotoxic cargo, the Pt II complexes in this case, only in the intracellular space. Currently, we are investigating the amount of uptake of {B 12 -CN-Pt II } and therapeutic action. 
